Entyvio subcutaneous injection 108mg syringe, from Takeda Pharmaceutical, contains vedolizumab (genetical recombination). This integrin blocker is approved for maintenance treatment of moderate-to-severe ulcerative colitis and Crohn’s disease in adults. It comes as 108mg x 0.68mL x 1 tube with YJ code 2399405G1025.
Entyvio subcutaneous injection 108mg syringe
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →